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Antikaliuretic action of trimethoprim is minimized by raising urine pH.
This study was designed to test the hypothesis that the antikaliuresis
caused by trimethoprim could be diminished by alkalinizing the luminal
fluid in the CCD, thereby converting trimethoprim from its cationic, active
form to an electroneutral, inactive form. Timethoprim-induced inhibition
of transepithelial Na transport was examined in A6 distal nephron cells
by analysis of short circuit current. The voltage-dependence of the
trimethoprim-induced block of Na channels was examined with patch
clamp recordings of A6 cells. The antikaliuretic effect of trimethoprim was
examined in vivo in rats pretreated with desoxycorticosterone and with
NH4CI to tower urine pH, and in rats also receiving acetazolamide to raise
urine pH. We found that the concentration of trimethoprim required to
inhibit the amiloride sensitive component of short circuit current by 50%
(IC50) was 340 rM (at pH 8.2) and 50 .tM (at pH 6.3). The IC50s of
protonated trimethoprim were similar (34 jsM at pH 8.2 and 45 /LM at pH
6.3). The mean time open for the high selectivity, Na channel was
reduced from 1679 387 msec to 502 98 msec with addition of i0— M
trimethoprim to patch pipette solution at the resting membrane potential
(Vpjpettc = 0 mV). Further decreases in mean time open were observed
as was reduced (that is, apical membrane hyperpolarization) to
—40 mV (mean time open = 217 85 mscc) and to —80 mV (mean time
open = 69 13 msec). In vivo, trimethoprim caused a > 50% reduction
in potassium (K) excretion due primarily to a fall in the [K1 in the
lumen of the terminal CCD. This effect of trimethoprim was markedly
attenuated in an alkaline urine induced by acetazolamide. We conclude
that it is the charged, protonated species of trimethoprim which blocks
epithelial Na channels. Increasing urinary pH decreases the concentra-
tion of the charged species of trimethoprim and minimizes its antikali-
uretic effect.
Drugs used in the treatment of Pneumocystis carinii pneumonia
(PCP) such as trimethoprim and pentamidine inhibit epithelial
sodium (Na) channels present in renal cortical collecting ducts
(CCD) [1—3]. Hence these drugs act in a similar fashion to
potassium (K) sparing diuretics, and their administration to
patients with the acquired immunodeficiency syndrome (AIDS)
likely contributes to the high incidence of hyperkalemia observed
in patients with AIDS who receive these antimicrobial agents
[4—61.
Amiloride is the prototypic epithelial Na channel inhibitor [7,
8]; it is a weak base, and its protonated species is the form that
inhibits epithelial Na channels by mechanisms which are voltage
dependent [8—12]. Trimethoprim is also a weak base with a PKa of
7.24 (Table 1) [13]. We reasoned that it is likely that the
protonated species of trimethoprim should be the form of the
drug that will block epithelial Na channels.
The purpose of the present study was to determine if the
tendency of trimethoprim to inhibit renal K excretion could be
abrogated by converting trimethoprim to an inactive, electroneu-
tral form in the lumen of the CCD. We speculated that when the
urine pH is above 7, the cationic form of trimethoprim will decline
appreciably. This could have a profound effect on trimethoprim's
ability to block epithelial Na channels, and thereby its secondary
inhibitory effect on renal K secretion. In the results to follow, we
provide direct evidence that it is the protonated species of
trimethoprim that blocks epithelial Na channels in a voltage-
dependent manner. Moreover, we demonstrate that the antikali-
uretic effect of trimethoprim was due to a low luminal concentra-
tion of K in the CCD ([K](cD). The low K excretion rates
attributed to trimethoprim were largely prevented by raising urine
pH. These data suggest that urine alkalization may ameliorate
trimethoprim-induced hyperkalemia in humans.
Methods
Chemicals
Trimethoprim was purchased from Sigma Chemical Corpora-
tion (St. Louis, MO, USA); it was diluted initially in DMSO as a
stock solution which was diluted further in Ringer's solution in
individual experiments. Desoxycorticosterone pivalate (DOCP)
was purchased from Ciba-Geigy, Animal Health; acetazolamide
was purchased from Cyanamid Canada Inc. (Montreal, Quebec,
Canada). Appropriate solvent vehicles were of highest purity and,
when added to the control bath by themselves, caused no change
in Na channel activity or short circuit current (I).
A6 distal nephron cell line cultures
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The methods are similar to those described previously [1—3, 14,
15]. Briefly, A6 cells derived from Xenopus laevis kidney (Amer-
ican Type Culture Collection, Rockville, MD, USA) or the A6
subclone 2F3 (a gift from Drs. B.C. Rossier and J.P. Kreahenbuhl)
were maintained in plastic tissue culture flasks at 28°C with 4%
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Table 1. pKs of epithelial Na channel blockers
Drug pK,
Triamterene [7] 6.5
Trimethoprim [13] 7.24
Amiloride [7, 8] 8.7
Pentamidinea 11.4
Unpublished observations, Fujisawa, Deerfield, IL, USA
CO2 in air as previously described [31.A6 cells passages 71 to 85
were used for patch clamp experiments and the A6 subclone 2F3,
passages 91 to 96, for transepithelial measurements. For patch
clamp experiments, A6 cells were plated at confluent density on
permeable, glutaraldehyde-fixed, collagen-coated Millipore-CM
filters (Millipore Corp., MA, USA) attached to the bottoms of
small lucite rings [2, 3, 14—161. For transepithelial experiments,
A6 cells were seeded on collagen-coated polycarbonate filters
(Costar, CA, USA) at a density of 0.5 to 1.0 X 106 cells/cm2 [1—31.
Transepithelial measurements
A6 cell monolayers were transferred to a modified Ussing
chamber and bathed in a Ringer's saline containing (in mM): 100
NaC1, 4 KCI, 2.5 NaHCO3, 1 KPO4, 1 CaC12, 11 glucose, and
buffered with either 10 MES (pH 6.3); or 10 Tris (pH 8.2) [1—3].
Electrical measurements were performed with a DVC-1000 volt-
age clamp (World Precision Instruments, FL, USA). The 'Scwas
allowed to stabilize before the addition of drug. The amiloride-
sensitive component of the short circuit current was determined
by adding io M amiloride to the luminal solution at the end of
each experiment.
Patch clamp recording and analysis
Patch pipette and extracellular bath solutions consisted of a
physiologic amphibian saline containing (in mM): 95 NaC1, 3.4
KC1, 0.8 CaCl2, 0.8 MgC12, and 10 HEPES (pH 7.4). Experiments
were performed at room temperature. Unitary channel events
were measured and analyzed as previously described [2, 3, 14—16].
The convention for applied voltage to the apical membrane patch
represents the voltage deflection from the patch
potential (that is, negative voltage = hyperpolarization; positive
voltage = depolarization of the resting membrane potential for
cell-attached patches). Inward current (pipette to cell) is repre-
sented as downward transitions in single channel records. We
used NPo (number of channels times the open probability) as a
measure of channel activity, and mean time open (<top,,n>) as a
measure of open state kinetics [2, 3, 14—161. Mean time open for
N observed channels was calculated as follows:
(T) x (NPo)
<topen> =
n/2
where n is the total number of transitions between states during
the total recording period T, and NPo is calculated as previously
described [2, 3, 14—16].
In vivo experiments
Male Sprague-Dawley rats (weight 350 to 550 g) were obtained
from Harlan Sprague Dawley, Inc. (Indianapolis, IN, USA). To
achieve bicarbonate-poor urine, rats received NH4CI, 300 mM in
5% (wt/vol) sucrose, in their drinking water for 24 hours prior to
the studies; the mean intake was 18 2.5 ml per day. To achieve
a reasonable urine flow rate, all rats were given 25 ml of 0.9%
(wt/vol) NaC1 per kg, intraperitoneally at the start of the experi-
ment. On the morning of the experiments, rats were given a single
intramuscular injection of 5 mg DOCP per kg body wt to ensure
that mineralocorticoids were not a limiting factor. Following these
preparations, each rat was placed in an individual metabolic cage
and urine collected every two hours by spontaneous voiding. The
cages were sprayed with silicone to facilitate rapid and complete
collections of urine. An arterial blood sample was also collected
following the final urine collection.
Studies
There were four groups of rats: (1) six rats received no
additional treatment; (2) 15 rats received trimethoprim (20 mg/
kg) as a single intraperitoneal injection as their sole treatment; the
trimethoprim was diluted in sterile water to a concentration of 10
mg/ml. To induce an alkaline urine pH, two additional groups of
rats were studied: (3) 12 rats received acetazolamide (5 mg/kg) by
intraperitoneal injection in addition to the same dose of tn-
methoprim given to group 2. (4) Finally, in group 4, eight rats
received acetazolamide alone at the above dose.
Analytical techniques
The concentrations of Na and K in plasma and urine were
determined by flame photometry (Radiometer, Copenhagen,
Denmark); chloride was measured by electromimetic titration
(Radiometer). Urine and plasma osmolality were measured as
previously described [17]. Urine pH, plasma pH and P02 in
arterial blood, were measured using a Radiometer blood gas
analyzer as previously described [17].
Calculations
The transtubular potassium gradient (111KG), a reflection of
the driving force for net K secretion in the CCD was calculated
using the formula: 11KG = (U/P)K/(U/P)oSm, as previously
described [18, 19].
Statistics
Mean time open is reported as one SD. ANOVA was used for
multiple comparisons [2, 3, 14, 15]. Results were considered
significant if P < 0.05. Statistics were performed with SigmaStat
(Jandel Scientific, San Rafael, CA, USA). For the in vivo studies,
results for the four groups were first compared by one-way
ANOVA. Results were considered significant if P < 0.05. For
parameters where ANOVA indicated a significant value, three
comparisons using Student's t-test were carried out: control versus
trimethoprim alone; trimethoprim versus trimethoprim plus ac-
etazolamide (to assess the effects of acetazolamide on tn-
methoprim treated rats); and acetazolamide alone versus aceta-
zolamide plus trimethoprim (to assess the effects of trimethopnim
on acetazolamide treated rats). The level of significance was
adjusted to 0.017 (0.05/3, the number of comparisons, the Bon-
ferroni correction).
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Buffer pH IC50 (TMP) IC50 (TMP)
8.2 340 34
7.4 120 49
6.3 50 45
that exposure of the patch membrane surface to intrapipette
trimethoprim significantly blocked apical Na channel activity.
Mean time open was reduced to 502 98 msec (N = 12). In the
presence of intrapipette trimethoprim, an additional decrease in
mean time open was observed as — was made increasingly
more negative (that is, apical membrane hyperpolarization; Fig.
2). At = —40 mV, mean time open fell to 217 85 msec
and at Vpjpette = —80 mV, the mean time open was only 69
13 msec (N 12). These data suggest that it is the charged,
protonated species of trimethoprim which blocks epithelial Na
channels.
Results
Trimethoprim block of high selectivity Na channels is
pH-dependent
To examine whether it is the protonated form of trimethoprim
that blocks Na channels, the pH of the solution bathing the A6
cells was adjusted to either pH 6.3 or 8.2 in order to change the
relative amounts of protonated trimethoprim (Fig. 1). The con-
centration of trimethoprim required to inhibit the amiloride
sensitive component of 'Sc (such as transepithelial Na transport)
by 50% (IC50) at pH 8.2 was 340 j.M (N = 6); the IC50 at pH of
6.3 was 50 LLM (N = 4). We previously reported an 1C5() of 120 jIM
at pH 7.4 [11. These data were used to calculate the concentra-
tions of protonated trimethoprim which inhibited the amiloride-
sensitive component of L. by 50%; these concentrations were
similar (between 34 and 49 jIM, Table 2) at the three different pH
values.
Trimethoprim block of high selectivity Na channels is
voltage-dependent
In cell-attached patches on the apical membrane of A6 cells,
high selectivity Na channels have all the characteristics of
mineralocorticoid-sensitive, amiloride-blockable, Na channels
found in the apical membrane of principal cells of the mammalian
CCD [2, 3, 14—16]. Under normal conditions (resting membrane
potential, Vpjpcttc = 0 mV, room temperature, physiologic
extracellular ion composition, and intact cell-attached configura-
tion) the mean time open for the high sensitivity Na channel was
1679 387 msec (N = 8). This is consistent with basal mean time
open values that we have measured previously [14]. Cell-attached
patches were then made with patch pipettes containing the usual
pipette saline plus 10 M trimethoprim. In A6 cells, we have
previously shown that this clinically-relevant, "urinaty" concen-
tration of trimethoprim reduced Na channel NPo by 83% [31. At
resting membrane potential (—V151, = 0 mV), we again found
In vivo studies
Rats fed NH4C1 for one day prior to the experiment developed
a mild rise in their plasma [H] (fall in the plasma pH), a small
fall in their plasma bicarbonate concentration, and their urine pH
was consistently below 6 (Table 3). Treatment with acetazolamide
alone led to a statistically significant, greater fall in the plasma
bicarbonate concentration than in the group treated with tn-
methoprim plus acetazolamide. The plasma K concentrations
were somewhat lower in the experimental groups than in the
control rats.
The key data are the urinary parameters. Urine flow rates were
not statistically different between the four groups by ANOVA (P
> 0.05). The urine K concentration did differ between the four
groups; rats treated with trimethoprim alone had a significant fall
in the urine K concentration compared to control, and this effect
was significantly blunted when acetazolamide was given together
with tnimethoprim. Similarly, the urine K concentration was
significantly lower in the group given trimethoprim with acetazo-
lamide than with acetazolamide alone. Results for urine K
excretion rate were parallel. Trimethoprim caused an approxi-
mately 50% fall in K excretion in both control and acetazolamide
treated rats; acetazolamide doubled K excretion in trimethoprim
treated rats.
The basis for changes in K excretion was analyzed using the
TTKG. The TTKG was diminished by close to 50% in tn-
methoprim treated rats (3.7 0.4) compared to controls (7.0
0.4). In rats treated with both trimethoprim and acetazolamide,
the YTKG was close to control (7.8 0.8) and with acetazolamide
alone, the TFKG was even higher than control (11.2 0.7).
Therefore, the changes in ]ITKG appeared to largely account for
the changes in urinary K excretion rate.
Urinary Na excretion differed between the groups, but the
only statistically significant difference in the comparisons made
was between trimethoprim alone versus trimethoprim plus aceta-
zolamide. Acetazolamide caused a large natriuresis.
Table 2. Effects of pH on the inhibition of amiloride-sensitive short
circuit current by trimethoprim (TMP) and by protonated trimethoprim
(TMP)
100
80
60
ci,
a)
ci)
ci)
20
E(a
0i0 i0 1O iO 102
Trimethoprim, M
Fig. 1. Effect of trimethoprim on transepithelial Na transport (I) in A6
distal nephron cells. Results are expressed as percent inhibition of the
amiloride-sensitive component of short circuit (I) in A6 cells bathed in
solutions buffered at pH 6.3 (•) or pH 8.2 (0). The results are the mean
(± SEM) values from 4 experiments (pH 6.3) or 6 experiments (pH 8.2).
The IC50s obtained with varying buffer pH are listed. The concentration
of trimethoprim was determined by the Henderson-Hasselbalch equation.
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Fig. 2. High selectivity, Na channel block by trimethoprim. (A) Single channel recordings from cell-attached patches containing only one Na channel.
At resting membrane potential = 0 my), the control trace shows basal activity with typically long mean open times (753 229 msec). In
another patch, channel block was observed with exposure to intrapipette 10 M trimethoprim at = 0mV. In the same patch, rapid "flickering"
between the open and closed states appeared when the apical membrane was hyperpolarized by 40 and 80 mV. Corner frequency was 1 Khz, sampling
was performed at 2 Khz, and additional software filtering was 200 Hz. "C" marks the closed state and "01" marks the current level with one Na' channel
open. (B) Plot depicts mean time open (<t0>) in cell-attached patches containing multiple Na channels. Control patches (N = 8) are plotted on
the left and patches exposed to intrapipette 10 M trimethoprim (N = 12) are plotted on the right. Enhanced trimethoprim-induced blockade was
observed with hyperpolarization from of 0 mV to —80 mV.
Table 3. Effect of trimethoprim and acetazolamide on renal K-
secretion
Control
(N=6)
TMP
(N= 15)
TMP + ACZ
(N= 12)
ACZ
(N=8)
[H ] plasma flM
[HCO3] plasma mM
48 1.8
22 1.1
43 1.1
24 1.1
47 2.1
20 0.8"
49 1.4
16 0.8"
[K] plasma mivi 4.3 0.2 3.4 0.1" 3.6 0.1 3.6 0.1
Flow rate p1/minI 19 2.7 22 5.8 34 9.9 36 6.6
kg body wt
[K]urjne mM
UKV nmol/min/
211 18
3784 430
78 11'
1525 330"
144 19"
3486 623"
224 37
7129 414C
kg body wt
U,,,
TFKG
<6
7.0 0.4
6.0 0.1
3.7 0.4a
7.8 01b
7.8 0.8"
7.8 0.1
11.2 0.7"
UN,V nmol/min/ 3318 547 2121 548 7311 1667h 8064 981
kg body wt
Male Sprague-Dawley rats received NH4CI in their drinking water for
24 hours prior to the studies, DOCP on the morning of the experiment,
and intraperitoneal 0.9% NaCI at the start of the experiment as described
under Methods. Four groups of rats were studied: (1) no additional
treatment; (2) trimethoprim (TMP) alone; (3) trimethoprim plus aceta-
zolamide (ACZ); and (4) acetazolamide alone. The results are reported as
the mean sEM; the number of rats is shown in parentheses. For details
concerning statistics, see Methods.
a P < 0.017 for the effect of TMP as compared to normal rats.
"P < 0.0 17 for the effect of ACZ in TMP treated rats
"P < 0.0 17 for the effect of TMP in ACZ treated rats
Discussion
Transepithelial Na transport across high resistance, Na'
transporting epithelia is mediated by an amiloride-sensitive Na'
channel in the apical plasma membrane and a Na,K-ATPase
which is localized to the basolateral plasma membrane. Inhibition
of epithelial Na" channels in the distal nephron secondarily
inhibits K" secretion [7]. Previous studies of the amiloride-
induced block of epithelial Na" channels have shown that it is the
charged, protonated species which blocks the Na' channel [8—12].
Trimethoprim is a weak base (Table 1) and our data (Figs. 1 and
2, Table 2) suggest that, as in the case of amiloride, only
protonated trimethoprim blocks Na channels.
We have previously shown that amiloride blockade of the highly
selective Na' channel in primary cultured rabbit CCD principal
cells is also enhanced by membrane hyperpolarization. This
observation would be predicted from the model for voltage-
dependent amiloride block of the epithelial Na' conducting pore
reviewed by Palmer [101. Accentuating the cell negative potential
draws the positively charged amiloride molecule into the channel
pore, and retards its dissociation and return to the mucosal
solution. In A6 cells, single channel studies by Eaton and Ma-
runaka [9] measured amiloride blocking on- and off-rates that
were compatible with an amiloride binding site within the pore,
sensing 15% of the membrane voltage. The trimethoprim-induced
block of epithelial Na" channels is also voltage dependent,
providing evidence that it is the protonated, or charged species of
trimethoprim which inhibits Na channels.
Studies in vivo
The excretion of K' is a function of two factors, the flow rate
in the CCD and the [K] achieved in the luminal fluid of the
terminal CCD [201. To raise this luminal [K], one needs an
electrochemical driving force which is generated by the electro-
genic reabsorption of Na" in this nephron segment. Electrogenic
reabsorption, in turn, depends on a relatively more rapid reab-
sorption of Na' ions than C1 ions [21]. Hence the finding of a
low TTKG or a low [K"]CCD after administration of trimethoprim
suggests that there was less electrogenic reabsorption of Na" in
the CCD. This, together with the demonstration of inhibition of
the Na channel by trimethoprim in A6 cells (Figs. 1 and 2, Table
BA
Control
—Vpipet = 0 mV — 01
0.35 pA [.......
Intrapipette i0- MTMP 800 msecTfirurrUUThw I
—Vpipet = 0 mV
Intrapipette 1 O M TMP
— C
—Vpipet = —40 mV
—01
Intrapipette 1 0 M TMP
—Vpipet = —80 mV
2000
C.)
ci)
1600
1)
0
ci)
. 800
C
400
—Vpipet
(mV)
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2) pIus the obvious renal Na wasting in patients [1] are all
consistent with relatively slower reabsorption of Na rather than
relatively faster reabsorption of CL [20] as the most important
component of the pathophysiology. Since all rats in our study
received a bolus of saline to expand their ECF volume and create
a natriuresis, this model was not an ideal one to reveal the
natriuretic actions of trimethoprim.
The hypothesis that was tested in vivo was that the cationic form
of trimethoprim was the biologically active form of the drug.
Given that its PKa was in the range of pH of the urine that is seen
in vivo (Table 1), the effect of a bicarbonate diuresis was studied.
An alkaline urine produced by the administration of acetazol-
amide prevented a trimethoprim-induced low TFKG, and it
increased renal K excretion (Table 3).
Bicarbonaturia may also have three other effects to augment
the rate of excretion of K. First, an increase in flow rate in the
CCD due to an enhanced delivery of electrolytes might con-
tribute to the increase in K excretion observed in animals
receiving trimethoprim and acetazolamide. Indeed, there was a
higher rate of excretion of Na + K in rats treated with
trimethoprim + acetazolamide as compared to trimethoprim
alone (Table 3). Nevertheless, this augmented kaliuresis was
accompanied by a much higher urine K concentration and
TTKG. Second, a relatively high concentration of bicarbonate
in the CCD may inhibit CL reabsorption, and thereby enhance
K secretion via a more negative intraluminal negative voltage
as hypothesized by Velasquez, Wright and Good [221. If this
mechanism were operating to an important extent in the
animals treated with trimethoprim and acetazolamide, one
would expect enhanced Na-wasting compared to that seen
with acetazolamide alone, since the trimethoprim would limit
Na reabsorption, and the Na would then be excreted
together with the non-reabsorbed CL. In fact, Na excretion
rates were comparable in these two groups, suggesting that
diminished CL reabsorption due to enhanced HCO3 delivery
to the CCD was not a major mechanism of enhanced K
excretion in acetazolamide-treated rats. Third, it has been
suggested that the bicarbonate anion, when delivered to the
CCD, is a nonreabsorbable anion, and thereby directly en-
hances K secretion in this segment of the nephron [221. We do
not believe this was a major mechanism for K secretion
because nonresorbable anions augmented K excretion only
when the concentration of Cl in the lumen was < 15 mmol/liter
[221.
In summary, the evidence from the in vivo studies suggests that
acetazolamide-induced bicarbonaturia causes trimethoprim to be
converted from its protonated to its neutral form, and thereby
prevents its Na channel blocking activity which in turn abrogates
the trimethoprim-induced diminished K secretion. Other fac-
tors, such as a higher urine flow rate and reduced CL reabsorp-
tion may also contribute, but evidence for these mechanisms was
not found in our study.
Clinical implications
Patients with AIDS may be at greater risk of developing
hyperkalemia than are other patients receiving trimethoprim [1, 2,
6, 13, 23, 24]. Either a higher intake or a lower output of K could
be responsible for their tendency to hyperkalemia. Since there is
unlikely to be a greater dietary intake of K in these patients who
are often cachectic, the likeliest mechanism is a low excretion of
K1. K excretion depends on the flow rate and [K]0 in the
terminal CCD. When ADH acts, the osmolality of luminal fluid in
the terminal CCD should equal that in plasma [251. At this fixed
osmolality, flow rate is directly proportional to osmole excretion
rate [26]. Since normal subjects have urea as their principal urine
osmole, a low urea excretion rate could lead to a low flow rate in
the CCD. Indeed, a low osmole (that is, urea) excretion rate may
contribute to a lower rate of K excretion in patients with AIDS
who are treated with trimethoprim [271.
A second mechanism for impaired renal K excretion is that
due to a very low [KI in the luminal fluid of the CCD. In the
context of the low K excretion observed in these patients, a low
open-probability of existing Na channels due to hypoaldosteron-
ism should first be ruled out [1]. More specific causes of a low
concentration of K in the lumen of the CCD related to tn-
methoprim would include either a higher dose of trimethoprim
and/or a less alkaline luminal fluid. Factors that might lead to
lower distal delivery of bicarbonate could include an acid ash diet,
more protein catabolism due to sepsis (leading to greater produc-
tion of H ions [28]), more reabsorption of bicarbonate in
proximal tubule cells (high angiotensin II associated with high
renin levels caused by extracellular fluid volume contraction)
and/or a lower pH in luminal fluid of the CCD because of
aldosterone stimulated H secretion in the CCD.
Concluding remarks
Since patients with AIDS who have PCP may best be treated by
continuing their antimicrobial therapy (including trimethoprim),
the aim should be to minimize renal side-effects of trimethoprim.
To this end, a high intake of NaCl can combat the salt-wasting
effects of the drug, and may even augment the kaliuresis by an
increased urine flow rate. Nevertheless, there is the potential for
giving too much or too little NaCl to accomplish these aims. From
the results reported in this manuscript, we suggest that alkaliniz-
ing the urine with acetazolamide (250 mg) is a rational additional
therapeutic measure to augment the excretion of Kt Enough
NaHCO3 should be given to avoid metabolic acidosis and suffi-
cient NaC1 to defend the extracellular fluid volume. Careful
monitoring of extracellular fluid volume, acid-base balance, urine
pH and the plasma K concentration will be important. Finally,
the effects of acetazolamide on trimethopnim-induced inhibition
of renal K secretion should not be viewed as a unique phenom-
enon. Other epithelial Na channel inhibitors (that is, tniam-
terene; Table 1) with PKa5 in the range of pH values that exist in
the CCD urinary space may be less efficacious when urine pH
values are higher with acetazolamide. As amilonide and pentam-
idine have higher PKa values (Table 1), their effects on renal K
secretion should be insensitive to acetazolamide.
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